Compare CVS Health Corp (CVS) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Invesco NASDAQ 100 ETF — how do they compare? CVS Health Corp trades at $94.47 (market cap $119.58B), while Invesco NASDAQ 100 ETF trades at $298.65. The key difference: CVS Health Corp pays a 2.84% dividend while Invesco NASDAQ 100 ETF pays none, and Invesco NASDAQ 100 ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| CVS | QQQM | |
|---|---|---|
Market Cap | $119.58B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $110.60 | $307.23 |
52-Week Low | $65.51 | $229.87 |
Enterprise Value | $181.93B | — |
Dividend Yield | 2.84% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $94.12, down 1.62% today, but maintains strong analyst support with 33 buy ratings and a $115.90 consensus price target. The company delivered three consecutive earnings beats in 2026, with Q2 EPS of $2.58 beating expectations by 38%. Technical indicators show mixed signals with bullish oscillators but bearish moving averages, while fundamentals reveal solid revenue growth to $402.07B in 2025 despite margin compression.
CVS presents a compelling value opportunity with attractive valuation ratios (P/S: 0.29, P/B: 1.5) and strong institutional confidence. Near-term catalysts include continued Aetna recovery and healthcare services expansion, though risks include 2027 PBM pressures and margin volatility. The stock offers 23% upside to analyst targets with defensive healthcare positioning.
QQQM trades at $298.50, up 0.58% with a bullish technical outlook supported by moving averages. The ETF tracks the Nasdaq-100 index with exposure to large-cap tech stocks. Recent news highlights QQQM's lower expense ratio advantage over QQQ at $15 annually versus $18, making it an attractive cost-efficient option for Nasdaq-100 exposure. The fund has demonstrated strong historical performance with approximately 14% average annual returns since inception.
The outlook remains positive given Nasdaq's tech-led rally potential in H2 2026, though investors face concentration risk in mega-cap tech holdings. Key risks include market volatility and potential regulatory scrutiny of large tech companies. QQQM offers efficient Nasdaq-100 exposure with competitive fees for long-term growth investors seeking tech sector leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Invesco NASDAQ 100 ETF
QQQM is an ETF designed to track the performance of the NASDAQ-100 Index. It provides exposure to the 100 largest non-financial companies listed on the NASDAQ. Positioned as a lower-cost and more long-term-investor-friendly alternative to its peer QQQ, QQQM offers the same fundamental market exposure but typically has a lower share price and is structured to appeal to investors focused on accumulation rather than active trading.
Read more on QQQM →
